German Researchers Detail Efficacy of AMDL's DR-70 Cancer Test as Tumor Marker for Ovarian Carcinoma
Know zip about them, but seems relevant...
TUSTIN, Calif., Feb. 27 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL - News), developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that researchers from Johannes Gotenberg University, Germany, tested the diagnostic validity of the Company's DR-70® cancer test kit compared to CA-125, the standard test, as a tumor marker for the detection of ovarian carcinoma.
The researchers simultaneously investigated the serum activities of the two tests with 61 preoperative patients with histologically confirmed ovarian carcinoma and one hundred healthy people. The specificity for DR-70® in the test was 100 percent (determining the presence of cancer) and sensitivity (determining the type of cancer) was 83.6 percent, 13.1 percent higher than the CA-125 test.
The German researchers concluded that "DR-70® represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA-125." The study is published in the German Journal of Obstetrics and Gynecology.
The researchers in the paper write that the DR-70® immunoassay quantifies the amount of fibrin degradation products in the body, which is produced from malignant cells. DR-70® "has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer," the German researchers said.
Gary Dreher, AMDL CEO, said the Company is pleased with the research. He emphasized that AMDL's primary objective remains receiving U.S. Food & Drug Administration clearance to market DR-70®, which would simultaneously increase market awareness and acceptance in the international marketplace.
About AMDL
AMDL, Inc. (Amex: ADL - News), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70® non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70® was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70® have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70® can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at www.amdl.com. |
